Nerve Ultrasound of Peripheral Nerves in Patients Treated with Immune Checkpoint Inhibitors

Background and Objectives: Immune checkpoint inhibitors (ICIs) have enriched tumor therapy, improving overall survival. Immunotherapy adverse events (irAEs) occur in up to 50% of patients and also affect the peripheral nervous system. The exact pathomechanism is unclear; however, an autoimmune process is implicated. Thus, the clinical evaluation of irAEs in the peripheral nervous system is still demanding. We retrospectively analyzed nerve ultrasound (NU) data of polyneuropathies (PNPs) secondary to checkpoint inhibitors. Materials and Methods: NU data of patients with PNP symptoms secondary to ICI therapy were retrospectively analyzed using the Ultrasound Pattern Sum Score (UPSS) as a quantitative marker. Our findings were compared with a propensity score match analysis (1:1 ratio) to NU findings in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and chemotherapy-associated PNP patients. Results: In total, 10 patients were included (4 female, mean age 66 ± 10.5, IQR 60–77), where NU was performed in 80%. The UPSS obtained ranged from 0 to 5 (mean 2 ± 1.6, IQR 1–2.5). The morphological changes seen in the NUs resembled sonographic changes seen in chemotherapy-associated PNP (n = 10, mean UPSS 1 ± 1, IQR 0–2) with little to no nerve swelling. In contrast, CIDP patients had a significantly higher UPSS (n = 10, mean UPSS 11 ± 4, IQR 8–13, p < 0.0001). Conclusions: Although an autoimmune process is hypothesized to cause peripheral neurological irAEs, NU showed no increased swelling as seen in CIDP. The nerve swelling observed was mild and comparable to ultrasound findings seen in chemotherapy-associated PNP.

[1]  S. Brandner,et al.  197 Checkpoint inhibitor associated neuritis a novel pathological entity , 2022, Journal of Neurology Neurosurgery & Psychiatry.

[2]  Yan Li,et al.  Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases , 2021, BioMed research international.

[3]  R. Lewis,et al.  European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision , 2021, European journal of neurology.

[4]  R. Lewis,et al.  European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision , 2021, Journal of the peripheral nervous system : JPNS.

[5]  A. Grimm,et al.  Nerve Ultrasound as Helpful Tool in Polyneuropathies , 2021, Diagnostics.

[6]  Julian Schardt Der Einsatz von Immuncheckpoint-Inhibitoren im onkologischen Alltag , 2020, Zeitschrift für Rheumatologie.

[7]  M. Payne,et al.  Toxicities associated with checkpoint inhibitors—an overview , 2019, Rheumatology.

[8]  Peter C Pan,et al.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition , 2019, Current Oncology Reports.

[9]  R. Gutzmer,et al.  Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook , 2019, Journal of clinical medicine.

[10]  L. Deangelis,et al.  Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy , 2019, Clinical Neurophysiology.

[11]  A. Kartolo,et al.  Predictors of immunotherapy-induced immune-related adverse events. , 2018, Current oncology.

[12]  Wei-min Li,et al.  Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials , 2018, Journal of Cancer Research and Clinical Oncology.

[13]  S. Attarian,et al.  Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review , 2018, Muscle & nerve.

[14]  Y. Nakatsuji,et al.  Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barré syndrome , 2018, Journal of the Neurological Sciences.

[15]  H. Axer,et al.  A look inside the nerve – Morphology of nerve fascicles in healthy controls and patients with polyneuropathy , 2017, Clinical Neurophysiology.

[16]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[17]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. Fujimoto,et al.  Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. , 2016, Japanese journal of clinical oncology.

[19]  Z. Fang,et al.  PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis , 2016, PloS one.

[20]  P. Saiag,et al.  Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. , 2016, The New England journal of medicine.

[21]  F. Hodi,et al.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.

[22]  R. Dummer,et al.  Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab , 2013, Cancer.

[23]  A. Tarhini Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management , 2013, Scientifica.

[24]  R. Strowd,et al.  Neurologic complications of immune checkpoint inhibitors , 2021, Neuro-Oncology for the Clinical Neurologist.

[25]  Ho Lam Chan,et al.  Immune checkpoint inhibitors: basics and challenges. , 2019, Current medicinal chemistry.